A study published in the Journal of Dermatology found that patients with psoriasis have an increased risk for cataracts and cataract surgery, with risks varying by treatment modality. The research was conducted by Yan-Jie Su from Taipei Veterans General Hospital in Taiwan.
An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.
Scientists at St. Jude Children's Research Hospital have identified a gene-regulatory pathway called COMPASS that enables regulatory T cells to maintain immune tolerance to trillions of bacteria in the human gut. The discovery, published in Science Advances, explains how the body prevents devastating autoimmune responses to intestinal microbes.
Scientists have discovered that EKODE, a metabolite of commonly consumed linoleic acid fat, binds to the GPR35 receptor to trigger inflammation and itching in psoriasis. Blocking this receptor in mouse models significantly reduced both inflammation and scratching behavior.
Researchers at La Jolla Institute for Immunology and University of Washington found that lupus patients have unusual mutations in neutrophils that generate novel peptides, which are recognized as foreign threats by T and B cells, driving autoimmune responses and antibody production.
Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.
A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.
A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.
Growing evidence is challenging the traditional view that allergic and autoimmune disorders are opposing forms of immune dysfunction, with researchers uncovering shared mechanisms between the two conditions that have historically been evaluated and treated separately.
A new study found that patients with autoimmune rheumatic disease who received updated or booster COVID-19 vaccines had significantly lower odds of COVID-related hospitalization compared to those who only received the initial vaccine series. The findings come as COVID hospitalizations have risen sharply in recent weeks.
Argenx announced its experimental drug FB102 met the primary endpoint in a Phase 2 study for celiac disease, providing first evidence that blocking CD122 can prevent gluten-induced intestinal damage. The company plans to advance the drug into Phase 3 development, though the news was overshadowed by a simultaneous setback in Sjögren's disease that sent shares falling.
The FDA has expanded the indication for baricitinib (Olumiant), a once-daily oral JAK inhibitor, to include adolescents aged 12 and older with severe alopecia areata. This marks the second JAK inhibitor treatment approved for adolescents with the condition.
Three participants have died in clinical trials of Novartis' chimeric antigen receptor T-cell therapy for autoimmune disease, prompting physicians to approach patient discussions with greater caution as the field remains in early stages of development.
Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.
Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.
Pfizer announced positive topline results from two pivotal Phase 3 studies showing LITFULO (ritlecitinib) significantly improved facial and total repigmentation compared to placebo at 52 weeks in patients with nonsegmental vitiligo. The studies represent the largest Phase 3 program to date for an oral systemic therapy in this indication.
Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.
Tech entrepreneur and anti-aging advocate Bryan Johnson announced he has created what he describes as a 'newborn' version of himself using stem cells, with the goal of growing replacement organs after being diagnosed with autoimmune gastritis. The controversial experiment represents his latest effort in his 'Don't Die' longevity campaign.